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Introduction
Doxorubicin is a widely-used anticancer agent and the
major limitation of its use is dose-related cardiotoxicity.1) At
present, doxorubicin cardiotoxicity is routinely screened
noninvasively by measurement of the left ventricular (LV)
ejection fraction (EF), but abnormal observations can be
made only when cardiac damage already has reached signi-
ficant proportions.2)
Recently, myocardial apoptosis was suggested as a common
mechanism of acute and chronic myocyte loss.3-5) In the
pathophysiology of cardiovascular disease, programmed cell
death of cardiomyocytes has been suggested to be an impor-
tant contributor because apoptotic cardiomyocytes have
been identified during hypoxia, ischemia, cardiac overload,
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Background: The aim of this study was to assess the feasibility of targeted ultrasound imaging on apoptosis with annexin A5
microbubbles (A5MB) in acute doxorubicin-induced cardiotoxicity.
Methods: Avidinated and octafluoropropan-filled phospholipid microbubbles were conjugated with biotinylated annexin A5.
To confirm the specific binding of A5MB, flow cytometry was performed with hydrogen peroxide induced apoptosis in rat
aorta smooth muscle cells incubated with fluorescein-5-isothiocyanate (FITC) labeled annexin A5 and A5MB. Adult male rats
were injected intraperitoneally with 5 mg/kg doxorubicin weekly for 3 weeks (n = 5). Control rats were injected with normal
saline (n = 5). At 24 hours after the final treatment, triggering imaging was performed 15 min after an intravenous bolus
injection of A5MB for washout of freely circulating microbubbles. After echocardiography, the heart was isolated for
histological detection of apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. 
Results: In the in vitro tests, fluorescence intensity was low for healthy cells and high for apoptotic cells when incubated
with FITC-labeled annexin A5 and A5MB. Rats treated with doxorubicin showed significant contrast opacification of the
myocardium on contrast echocardiography using A5MB. However, no opacification was observed in control rats. Apoptosis
was confirmed by TUNEL assay in doxorubicin treated rats.
Conclusion: Acute doxorubicin-induced cardiomyopathy based on early apoptosis can be assessed and imaged with targeted
ultrasound imaging using A5MB in rats.
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acute myocardial infarction, end-stage heart failure in vivo,
and anthracycline use.6)7) Doxorubicin induces apoptosis in
several cell lines and, in a rat model, the kidneys, intestines,
and cardiomyocytes.7-9) Therefore, the detection of apoptosis
could be an opportunity for the noninvasive exploration of
early cardiomyopathy. 
The detection methods used in most studies evaluating
apoptosis of the heart are based on the occurrence of DNA
fragmentation, such as the terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-end labeling (TUNEL) assay
and DNA laddering. However, in vivo detection of cell death
is not possible with TUNEL or DNA gel electrophoresis.10)
One of the earliest events after triggering cell death is the
externalization of phosphatidylserine (PS) to the outer leaflet
of the plasma membrane of the cell. Detection of PS expo-
sure can be easily achieved by the phospholipid binding pro-
tein annexin A5. In a number of in vitro and in vivo studies,
annexin A5 has been demonstrated to be a specific marker
for the early and late stages of cells undergoing programmed
cell death and that the protein is also suitable for the in situ
detection of cell death. Therefore, labeled annexin A5 pro-
vides a useful tool for in situ detection of cell death in vivo
and also, at least potentially, in clinical settings.11)
Imaging of cellular and molecular events with contrast-
enhanced ultrasound has recently been achieved with the use of
novel targeted microbubble contrast agents that are retained
within diseased organs.12) Unlike inert microbubble blood tra-
cers, targeted microbubbles were designed to adhere to specific
endothelial surface epitopes to allow ultrasonic detection of
these epitopes.13) The relative advantage of using ultrasound is
that it is well-balanced in terms of sensitivity and spatial resolu-
tion. In comparison to radionuclide imaging, ultrasound is
slightly less sensitive, mostly as a result of the influence of back-
ground tissue signal, but has superior spatial resolution. Other
potential advantages of ultrasound include its low cost, high
temporal resolution, and rapid data acquisition.14)
The aim of this study was to assess the feasibility of target-
ed ultrasound imaging of apoptosis with microbubbles con-
jugated with annexin A5 (A5MB) in acute doxorubicin-
induced cardiotoxicity models.
Methods
Preparation of microbubbles conjugated with 
annexin A5
Biotinylated microbubbles with lipid shells were prepared
by sonication (35 W, 4 minutes) of octafluoropropan gas
with aqueous dispersion of 5 mg/mL 1,2-distearoyl-sn-
glycero-3-phosphocholine (Avanti Polar Lipids, Inc., Alaba-
ster, AL, USA), 5 mg/mL polyethylenglycol distearate (Sigma-
Aldrich, St. Louis, MO, USA), and 2.5 mg/mL 1,2-distea-
royl-sn-glycero-3-phosphoethanolamine-N-[biotinyl (poly-
ethyleneglycol) 2000] (Avanti Polar Lipids, Inc.) in normal
saline. After sonication, the microbubbles were placed in a
tube and centrifuged for 3 minutes at 2,000 rpm. The
bottom saline was drained and 5 mL of saline was added to
the foam and the centrifuge was washed 2 times. Prepared
microbubbles were combined with NeutrAvidin (Pierce
Biotechnology, Inc., Rockford, IL, USA) for 30 min and
washed with saline. Then the microbubbles were combined
with biotinylated annexin A5 for 30 min and washed 2 times.
Human annexin A5 was produced by expression in Escheri-
chia coli. fluorescein-5-isothiocyanate (FITC)-labeled
A5MB for flow cytometry were prepared using FITC-
labeled NeutrAvidin.
in vitro study
Flow cytometry
Specific binding of A5MB to apoptotic cells was confirmed
by flow cytometry. Rat aorta smooth muscle cells (SMC)
were cultured over 70% confluency in Dulbecco’s modified
Eagle’s medium (GIBCO BRL, Rockville, MD, USA) with
10% fetal bovine serum and treated with hydrogen peroxide
100 µM. Three hours after the treatment, the cells were
collected and washed with phosphate-buffered saline (PBS)
and then resuspended in a binding solution of 500 µL (2%
BSA, 10 mM HEPES, 150 mM NaCl, 2.5 mM CaCl2, 1
mM MgCl2) and blocked for 1 hour at room temperature.
FITC-labeled annexin A5 and FITC-labeled A5MB were
added to cell suspensions. The reaction was incubated in the
dark for 20 minutes at room temperature and the cells were
washed 2 times with PBS. Samples were placed on a tube
and immediately analyzed on a FACS Calibur (Becton
Dickinson, Franklin Lakes, NJ, USA) to generate histograms
of green fluorescence intensity.
in vivo experiments
Doxorubicin cardiotoxicity model
Adult male Sprague-Dawley rats weighing 247 ± 6 g were
purchased from Harlan and maintained under standard con-
ditions at an animal care facility. The rats had free access to
standard rodent chow and water. After rats received subcuta-
neous buprenorphine (0.05 mg/kg; Hanlim Pharm., Seoul,
Korea) to provide analgesia, doxorubicin (Dong-A Pharm.,
Seoul, Korea) 5 mg/kg was injected intraperitoneally. This
treatment was repeated weekly for 3 weeks, resulting in a total
cumulative dose of 15 mg/kg per animal (n = 5). Control rats
were injected with the same volume of buprenorphine and
physiological saline instead of doxorubicin (n = 5). All the
experiments were performed according to the “Revised Guide
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for the Care and Use of Laboratory Animals Available”.15)
Contrast echocardiography using microbubbles
Rats were sedated with zoletil (50 mg/kg) and xylazine (5
mg/kg), which was administered intraperitoneally. Once
sedated, the femoral vein was cannulated for microbubble
administration.
Imaging was performed at 14 MHz with a linear-array
transducer interfaced with an ultrasound system (Vivid 7, GE
Vingmed Ultrasound, Horten, Norway). Images were acquir-
ed in a parasternal short axis view with the transducer fixed
in position with a free-standing clamp. Before microbubble
injection, baseline images were acquired. Gain settings,
depth, and focus were initially optimized and maintained
throughout the experiment. Ultrasound transmission was
then suspended, and 4 ×106 A5MB were injected as an
intravenous bolus.
Preliminary studies demonstrated that a bolus of 4 ×106
microbubbles resulted in visually strong, reproducible opaci-
fication of rat myocardium and the myocardial contrast was
no longer detectable by 15 minutes after injection. Based on
these observations, myocardial backscatter at 15 minutes
should derive predominantly from adherent microbubbles
and less so from the few remaining circulating microbubbles. 
Immediately after contrast injection, a very high concen-
tration of freely circulating microbubbles in the blood pool
was expected. Therefore, imaging was not resumed until 15
min after injection for retention of microbubbles in apop-
totic tissue and clearance of freely circulating microbubbles
in the blood pool. Intermittent electrocardiography-trigger-
ing imaging (mechanical index of 0.8) was then initiated at a
pulse interval of 1 cardiac cycle for several frames. Contrast
opacification of myocardium in the 1st frame was considered
as the signal coming from the adhered microbubbles. There-
fore, contrast enhancement in the myocardium in the 1st frame
and its disappearance within the subsequent frames were
considered as positive results. Images were recorded digitally
and analyzed offline.
Histological examination
The TUNEL assay was performed according to the manu-
facturer’s instructions (Chemicon, Temecula, CA, USA). In
brief, the excised heart tissues were fixed in 3.7% buffered
formaldehyde and embedded in paraffin. Five µm-thick tissue
sections were deparaffinized, rehydrated, and rinsed with
PBS. A positive control sample was prepared by treating
normal heart tissue with DNase I (10 U/mL, 10 min at room
temperature). Sections were pretreated with 3.0% H2O2,
subjected to the reaction with TdT enzymes for 37˚C for 1
hour and incubated in digoxigenin-conjugated nucleotide
substrate at 37˚C for 30 min. Nuclei exhibiting DNA frag-
mentation were performed by 3,3-diamino benzidine for 5
min. Apoptotic cardiomyocytes nuclei were stained dark
brown. Lastly, sections were counterstained with methyl
green and coverslipped. The sections were observed by light
microscopy.
Experiment protocol
At the beginning of the experiment and before adminis-
tering any treatment, baseline echocardiography was per-
formed in both groups to measure LV dimensions and LV
EF. Then, doxorubicin or saline treatment was begun and
repeated weekly for 3 weeks according to the experiment
group described above. At 24 hours after the final treatment,
LV performance was examined by conventional echocardio-
graphy and targeted ultrasound imaging using A5MB was
obtained as described above. Immediately after echocardio-
graphy, the rats were sacrificed and the entire heart was remov-
ed and processed for histological analysis.
Statistical analysis
Results are expressed as mean ± SD. Data were analyzed
with 2-tailed Student’s t tests and one-way ANOVA. Statis-
tical significance was defined as p < 0.05.
Results
Flow cytometry
The histograms of fluorescence intensity obtained by flow
cytometry represent specific bindings of FITC labeled anne-
xin-5-microbubbles to apoptotic SMC (Fig. 1). Compared
to healthy cells, apoptotic cells incubated with FITC-labeled
A5MB were characterized by a higher percentage of positive
fluorescence staining (3.7% vs. 91.4%). Fluorescence inten-
sity was low for healthy cells and increased when apoptotic
cells were incubated with FITC-labeled annexin A5 and
FITC-labeled A5MB. These results indicated that the A5MB
bind specifically to apoptotic cells.
Body weight and left vetricular performance
The body weight of control rats was significantly increased
at the end of the experiment and LV mass was slightly in-
creased during the experiment period in both groups. How-
ever, no significant change in LV dimensions and LV EF was
observed during the experiment in either group (Table 1).
There was also no significant difference in body weight and
LV performance between the two groups.
Targeted ultrasound imaging
Fig. 2 demonstrated the results of contrast echocardio-
graphy using A5MB. In rats treated with doxorubicin, the 1st
frame showed significant contrast opacification of myocar-
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dium; the signal coming from the adhered microbubbles
(Fig. 2A). These retained microbubbles were destroyed dur-
ing subsequent high mechanical index imaging. Therefore,
no opacification was observed in the 10th frame (Fig. 2B). In
control rats, unbound microbubbles dissipated during the
waiting period and no contrast enhancement was observed
in the 1st (Fig. 2C) or the 10th frames (Fig. 2D).
TUNEL assay
The result of the TUNEL assay revealed increased apop-
tosis frequencies for both the cardiomyocytes and endo-
thelial cells of doxorubicin-treated hearts compared to con-
trol hearts (Fig. 3). TUNEL-positive cardiomyocytes and
endothelial cells were significantly higher in the doxorubicin-
treated group than in the control group, which indicated
that doxorubicin induced apoptosis of cardiomyocyte and
endothelial cells (Fig. 4).
Discussion
The main finding of this study is that targeted ultrasound
imaging using A5MB is capable of identifying apoptosis in
acute doxorubicin induced cardiomyopathy. This study is
the first description of an ultrasound approach for detecting
apoptosis using a targeted contrast agent and has major impli-
cations for noninvasive detection of early apoptosis in doxoru-
bicin induced cardiomyopathy. In addition, it is encouraging
that apoptosis detection by ultrasound is possible in this
study before definite LV systolic dysfunction occurs.
Molecular imaging is a rapidly evolving discipline with the
goal of developing tools to display and quantify molecular
and cellular targets in vivo.16) Although techniques for mole-
cular imaging have been developed for essentially every form
of medical imaging, there are significant differences that
influence the choice of imaging methods in both research
and clinical settings. For the imaging of apoptosis, recombi-
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Table 1. Body weight and LV performance in doxorubicin treated and control rats
Control (n = 5) Doxorubicin (n = 5)
Baseline Week 3 Baseline Week 3
Body weight (g) 247.2 ± 5.2 289.4 ± 19.6* 247.4 ± 6.9 270.8 ± 20.7
LV mass (g) 1.12 ± 0.02 1.23 ± 0.08� 1.09 ± 0.06 1.21 ± 0.05�
LVEDD (mm) 7.2 ± 0.4 7.2 ± 0.4 6.9 ± 0.5 7.2 ± 0.6
LVESD (mm) 4.9 ± 0.4 5.0 ± 0.3 4.6 ± 0.5 4.9 ± 0.4
LVEF (%) 65.6 ± 5.6 63.3 ± 4.9 67.5 ± 5.0 66.1 ± 3.5
Data represent mean ± SD. *significantly different from week 0 (p < 0.01).�significantly different from week 0 (p < 0.05). LV: left ventricle, LVEDD: left 
ventricular end-diastolic dimension, LVESD: left ventricular end-systolic dimension, LVEF: left ventricular ejection fraction
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Fig. 1. Specific binding of FITC-labeled annexin A5 to apoptosis cells. Healthy cells (A). Healthy cells incubated with FITC-labeled annexin A5 (B).
Healthy cells incubated with microbubbles conjugated with FITC-labeled annexin A5 (C). Apoptotic cells incubated with FITC-labeled annexin A5 (D).
Apoptotic cells incubated with microbubbles conjugated with FITC-labeled annexin A5 (E). FITC: fluorescein-5-isothiocyanate.
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nant human annexin A5 has been radiolabeled with 99mTc,
and the feasibility of imaging apoptosis has been demons-
trated both in experimental and clinical cardiovascular
disease states.17-19) Bennink et al.20) recently showed that acute
doxorubicin induced cardiomyopathy based on early apop-
tosis can be imaged with 99mTc-annexin A5 scintigraphy in
the murine model.
In this study, we used microbubbles conjugated with
annexin A5 for targeted ultrasound imaging of apoptosis. In
comparison to radionuclide imaging, the high temporal
resolution, availability, rapid execution of imaging protocols,
and relatively low cost are features of targeted molecular
imaging with ultrasound that make this technique attrac-
tive.12) As microbubbles are pure intravascular tracers, mole-
cular imaging with contrast-enhanced ultrasound has focus-
ed on diseases such as inflammation, thrombus formation,
and angiogenesis, which are mediated by pathophysiologic
events that occur within the vasculature.14) In doxorubicin-
induced cardiotoxicity, both cardiomyocyte and endothelial
cell death can occur via apoptosis.21) Therefore, in this study,
retained microbubbles that produced contrast enhancements
were thought to be adhered to the apoptotic endothelium,
not to the apoptotic cardiomyocyte. However, we could not
entirely exclude the possibility of direct attachment of A5MB
to apoptotic cardiomyocytes by extravasation through the
disrupted microvessel. In this study, the direct visualization
of A5MB binding to apoptotic cell could not be performed
in in vitro tests nor in in vivo experiments.
The results of this study indicate that site-targeted ultra-
sound has the potential for non-invasive investigation of
early apoptosis preceding deterioration of LV systolic func-
tion in doxorubicin induced cardiomyopathy. However, a
destructive imaging protocol that includes a 15-minute delay
for wash-out may be difficult to apply clinically in the future,
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Fig. 2. Targeted ultrasound imaging with annexin A5 conjugated microbubbles in doxorubicin-treated rats (A and B) and control rats (C and D).
Significant contrast opacification of myocardium (arrows) was observed in the 1st frame (A). Initial contrast enhancement was dissipated during
subsequent high mechanical index imaging in the 10th frame (B). No contrast opacification was observed in the myocardium in the 1st frame (C). No
contrast opacification was observed in the myocardium in the 10th frame (D).
A B
C D
because precisely locating the heart before the first destruc-
tive pulse may be challenging. In addition, contrast opacifi-
cation was assessed by visual estimation rather than by a
quantitative method in this study, and a newer quantifica-
tion method may improve the reproducibility and practi-
cability of targeted ultrasound imaging.
In conclusion, acute doxorubicin-induced cardiomyopathy
based on early apoptosis can be assessed and imaged with
targeted ultrasound imaging using microbubbles conjugated
with annexin A5 in rats. This investigation model may lead
to interesting applications during in vivo evaluations of cardio-
myocyte apoptosis in cardiomyopathy.
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